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Background: Adiposity has been linked to both higher risk of asthma and reduced lung function. The effects of
adiposity on asthma may depend on both atopic status and gender, while the relationship is less clear with respect
to lung function. This study aimed to explore longitudinal weight changes to changes in forced expiratory volume
in first second (FEV1) and forced vital capacity (FVC), as well as to incident cases of asthma and wheezing,
according to atopy and gender.
Methods: A general population sample aged 19–72 years was examined with the same methodology five years
apart. Longitudinal changes in weight, body mass index, waist circumference, and fat percentage (bio-impedance)
were analyzed with respect to changes of FEV1 and FVC (spirometry), and incidence of asthma and wheezing
(questionnaire). Gender, atopy (serum specific IgE-positivity to inhalant allergens) and adipose tissue mass prior to
adiposity changes were examined as potential effect modifiers.
Results: A total of 2,308 persons participated in both baseline and five-year follow-up examinations. Over the entire
span of adiposity changes, adiposity gain was associated with decreasing levels of lung function, whereas adiposity
loss was associated with increasing levels of lung function. All associations were dependent on gender
(p-interactions < 0.0001). For one standard deviation weight gain or weight loss, FEV1 changed with (+/−)
72 ml (66-78 ml) and FVC with (+/−)103 ml (94-112 ml) in males. In females FEV1 changed with (+/−) 27 ml
(22-32 ml) and FVC with (+/−) 36 ml (28-44 ml). There were no changes in the FEV1/FVC-ratio. The effect of
adiposity changes increased with the level of adipose tissue mass at the start of the study (baseline), thus, indicating an
aggregate effect of the total adipose tissue mass. Atopy did not modify these associations. There were no statistically
significant associations between changes in adiposity measures and risk of incident asthma or wheeze.
Conclusions: Over a five-year period, increasing adiposity was associated with decreasing lung function, whereas
decreasing adiposity was associated with increasing lung function. This effect was significantly greater in males than in
females and increased with pre-existing adiposity, but was independent of atopy.
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Adiposity has consistently been associated with asthma
[1] and has also been associated with impaired lung
function, e.g. as assessed by decreased levels of forced
expiratory volume in first second (FEV1) and forced
vital capacity (FVC) [2-6]. Thus, adiposity may influ-
ence the lungs in several ways, e.g. through inflammation
leading to asthma-like, obstructive changes, or in terms
of a mechanical impact on lung function (restrictive
changes).
Adiposity increases the risk of asthma and may cause
more severe symptoms along with a reduced response
to medications [1,7,8]. Some studies have indicated
that these effects are stronger in non-atopic individuals
than atopic individuals [9-11], although contrary re-
sults also have been noted [12]. Further, adiposity has
been reported to be more strongly associated with
asthma types characterised by non-eosinophilic inflam-
mation rather than by eosinophilic inflammation [13].
However, it has not been investigated whether adipos-
ity also has differential effects on lung function in
atopic and non-atopic individuals or in individuals
with or without eosinophilic inflammation in the air-
ways. Underlying pathological processes, such as eosino-
philic or neutrophilic inflammation [14], could possibly
modify the longitudinal relationship of adiposity with lung
function.
Mechanically, adiposity may cause an extra load on
the thoracic cage [15], increase the intra-abdominal
pressure, and impede the movements of the diaphragm
[16]. This has in smaller experimental settings been re-
ported to decrease static lung volumes and lead to
breathing at smaller tidal volumes [17]. Cross-sectional
studies have suggested that these changes are stronger
in persons with predominantly abdominal adiposity
than in persons with predominantly general adiposity
[18]. Yet, prospective population based studies are
sparse and have assessed adiposity changes mainly by
weight or BMI [2,3,19-22], except from one study that
included waist and hip circumferences but not FVC
[4]. Therefore, studies quantifying longitudinal changes
of lung function with respect to different adiposity
phenotypes may add further information about the
longitudinal relationship between adiposity and lung
function.
This prospective general population study aimed to in-
vestigate the association of longitudinal changes in weight,
body mass index (BMI), waist circumference (WC),
and fat percentage with longitudinal changes in FEV1
and FVC, and with concomitant incidence of asthma
and wheezing. Further, we examined whether these associ-
ations were modified by gender, atopy, or eosinophilic
inflammation of the lower airways as reflected by forced
expiratory nitric oxide (FENO).Methods
Study population
The current study used already sampled data from the
Health2006 study and the Health2006-follow-up study
conducted five years apart. The participants in the base-
line Health2006 cohort were drawn as a random sample
from the background population aged 18–69 years, living
in 11 municipalities in the south-western part of suburban
Copenhagen. A total of 3471 individuals (44.7%) entered
the study and participated in the health examination,
which took place in 2006–08 (Health2006 baseline [23]).
In 2011–12, participants in the baseline Health2006 were
invited for a 5-year follow-up examination including es-
sentially the same study protocol. A total of 3,405 were
eligible for invitation (21 had emigrated and 45 died). A
total of 2,308 (68.6%) agreed to participate and were re-
examined between November 2011 and November
2012. Fourteen participants did not have valid measures
of either FEV1 or FVC at either baseline or follow-up
and were excluded from the study, which for the main
analyses was based on 2,294 participants. All partici-
pants gave written informed consent before taking part
in the study, which was approved by the ethics com-
mittee of the Capital Region of Denmark, Copenhagen
(KA20060011).
Questionnaire data
Information on socio-demographic variables, leisure time
physical activity, smoking habits, chronic illnesses, respira-
tory symptoms, and medication were obtained from a
questionnaire that was mailed to and answered by the par-
ticipants before their visit to the research centre. Asthma
was defined according to the ECRHS criteria [24] as a
confirmatory answer to at least one of the following three
questions ‘Have you been woken by an attack of shortness
of breath at any time during the last 12 months?’, ‘Have
you had an attack of asthma within the last 12 months?’
and ‘Are you currently taking any medication (including
inhalers, aerosols or tablets) for asthma?’ Wheezing with-
out a cold (in the following referred to as wheezing) was
defined as a confirmatory answer to ‘Have you had wheez-
ing or whistling in your chest at any time during the last
12 months?’ combined with a confirmatory answer to ‘If
yes, have you had this wheezing or whistling when you did
not have a cold?’. Smoking was recorded as pack years
(one pack year equalling one pack of cigarettes per day for
a year) and categorised in five levels: (1) never smokers,
(2) 0- ≤ 10, (3) 10- ≤ 30, (4) 30- ≤ 50, or (5) more than 50
pack years but was also used as a continuous measure.
Educational level was categorised as: (1) less than 2 years,
(2) skilled worker, (3) less than 3 years, (4) 3–4 years,
and (5) more than four years. All questions used in the
present analyses were identical in the baseline and
follow-up studies.
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and FENO
Anthropometric measures were obtained with participants
in light clothing and without shoes. Height was measured
to the nearest cm, weight to the nearest 0.1 kg, and body
mass index (BMI) was calculated as kg/m2. Waist circum-
ference (WC) was measured to the nearest cm using a
tape measure midway between the lower rib margin and
the iliac crest. Fat percentage was measured using a foot-
to-foot Tanita Body Composition Analyzer (TBF-300,
TANITA Corporation of America, Inc., Illinois, U.S.A.).
Spirometry was performed according to American Thoracic
Society and the European Respiratory Society (ATS/ERS)
standard [25] using Spiro USB Spirometers (MicroMedical
Limited, Rochester, Kent, UK). Spirometers were checked
daily with a 3-liter calibrated syringe, and checked every
six months with a decompression flow simulator [26].
FENO measurements were performed only at baseline
using a NIOX MINO (Aerocrine AB, Stockholm, Sweden).
A dynamic flow restrictor yielded a constant flow rate of
50 mL/s, in accordance with recommendations of the
ATS/ERS guidelines for FENO measurement [27]. Nitric
oxide concentrations between 5 and 300 ppb were mea-
sured and measurements below 5 ppb were set to zero by
the NIOX MINO. Nitric oxide concentrations above
20 ppb were considered high.
Biomarkers
Baseline serum samples were analysed for serum specific
IgE against the four most clinically important inhalant
allergens in Denmark: birch, grass, cat, and the house
dust mite Dermatophagoides pteronyssinus, using the
ADVIA Centaur Specific IgE assay [28]. Atopy was de-
fined as at least one positive test (≥0.35 kilo units/L)
against specific IgE. Plasma glucose concentrations were
analysed by a hexokinase/glucose-6-phosphate dehydro-
genase assay (Roche Diagnostic, Germany), and insulin
concentrations were measured by fluoroimmunoassay
technique (Dako Diagnostics Ltd., UK). The homeostatic
model assessment-insulin resistance (HOMA-IR) index
was calculated as: fasting plasma glucose (mmol/L) x fast-
ing serum insulin (mU/L)/22.5 and applied only to the
non-diabetic individuals. High-density lipoprotein (HDL)
and triglyceride concentrations were measured by stand-
ard enzymatic techniques (Roche Diagnostic, Germany).
Statistics
We used the R-statistical package, version 3.0.2 (http://
www.r-project.org/) for all analyses. All p-values are two-
tailed and statistical significance defined as p <0.05.
P-values of likelihood ratio tests were used to test for
significance of all multivariate analyses. We used linear re-
gression and checked for equal residual variance across
the full range of all exposure variables to check the linearmodel assumptions. We also tested possible non-linear as-
sociations by dividing the exposure variables in splines
and by testing the quadratic term of the variables in the
regression models. For our main analyses, we used abso-
lute or percentage changes (between baseline and five-
year follow up) of the adiposity measures to changes in
FEV1 and FVC. The changes of FEV1 (or FVC) were
modelled as five-year FEV1 (or FVC) adjusted for FEV1
(or FVC) at baseline. We also tested the ‘reverse’ associ-
ation of baseline lung function measures to changes of
adiposity measures. The adiposity measures were standar-
dised by division of each measure by its own standard
error to ease interpretation of the regression coefficients
and to ease a comparison of the magnitude of effects be-
tween the different adiposity measures. In analyses of inci-
dence of asthma and wheezing, logistic regression was
used, similar model checks were applied, and the adiposity
measures were categorised in four equally sized groups by
quartiles of their respective distributions. Possible interac-
tions were tested by adding an interaction term to the
regression models, e.g. (adiposity measure*atopy) or
(adiposity measure*gender). Finally, all analyses were
repeated with s-Trig, s-HDL, and HOMA-IR included
in the models to test whether these metabolic markers
would attenuate the estimates found for adiposity. Sensitivity
analyses included exclusion of the lower and upper 0.0025,
0.005, 0.01 fractiles of the adiposity measures, as well as sep-
arate analyses in non- and never smokers, and in younger
or older (age categories were +/− 40, +/−45, +/−50 years)
individuals.
Finally, we made a simulation-model based on randomly
generated heights, BMI-levels, and levels of lung volume
dependent on height. This model gives an example of how
adipose tissue above a certain ‘person-dependent ideal’
would influence lung function (Additional file 1).
Results
The baseline characteristics of the study population are
given in Table 1. All characteristics are listed separately
for participants and non-participants in the follow-up
study. Of note is that non-participants as compared to
participants had significantly higher levels of adiposity
measures and higher levels of FEV1 and FVC. However,
the baseline associations of adipose tissue levels with
asthma, wheezing, FEV1 or FVC were not significantly
different between participants and non-participants, all
p-values for interaction between participation and each
adiposity measure were between 0.12 and 0.98. Sensitivity
analyses did not change the pattern of results presented.
From baseline to five-year follow-up, lung function
was inversely associated with the level of adiposity as
reflected by all four adiposity measures. In participants
with weight gain, lung function declined; whereas in par-
ticipants with weight loss, lung function increased to a
Table 1 Baseline characteristics of the study population according to participation in the five-year follow-up study
Participants follow-up Non-participants follow-up
N = 2294 N = 1163
Mean Sd n miss Mean Sd n miss
Age (y) 50.02 12.49 48.02 13.98
FEV1 (liter) 3.16 0.79 9 3.04 0.88 5
FVC (liter) 4.03 0.96 9 3.89 1.06 5
N % group N % group
Gender
Males 1048 45.7 495 42.6
Adiposity measures
18.5 > BMI (kg/m2) 38 1.7 27 2.3
18.5 < =BMI < 25 (kg/m2) 1096 47.8 491 42.2
25 < =BMI < 30 (kg/m2) 839 36.6 408 35.1
30 < =BMI (kg/m2) 319 13.9 2 237 20.4
WC, normal§ 1748 76.2 359 50.7
WC, high§ 545 23.8 2 349 49.3 3
Serum lipids
HDL, normal§ 2036 89.1 10 993 86.3 13
HDL, low§ 249 10.9 158 13.7
Triglyc <150 mg/dl 1901 83.2 887 77.1
Triglyc 150–500 mg/dl 230 10.1 161 14.0
Triglyc > = 500 mg/dl 154 6.7 10 103 8.9 13
Atopy, asthma, wheezing
Atopy*, not present 1741 75.9 924 79.4
Atopy*, present 553 24.1 239 20.6
Asthma, not present 1872 82.2 906 78.9
Asthma, present 405 17.8 17 242 21.1 15
Wheezing, not present 1974 86.7 915 79.9
Wheezing, present 303 13.3 17 230 20.1 18
Lifestyle
Smoking, never 1027 48.2 18 417 38.9
Smoking, 0-≤ 10 pack years 492 23.1 253 23.6
Smoking, >10 pack years 613 28.8 403 37.6 89
Alcohol, no drinking 225 10.1 159 14.3
Alcohol 1–14 units/week 1448 65.0 714 64.4
Alcohol >14 units/week 555 24.9 66 236 21.3 54
Education§, none 239 10.5 215 18.8
Education§, 1 year/practical 543 23.9 272 23.8
Education§§, 2–3 years 943 41.4 450 39.3
Education§§, > = 4 years 551 24.2 18 208 18.2 18
FEV1, forced expiratory volumes first second; FVC, forced vital capacity; BMI, body mass index; WC, waist circumference; Diabetes*, either self-reported diabetes or
fasting p-glucose > =7.1 mmol/L; HDL, serum level of high-density lipoprotein; Triglyc, serum level of triglyceride; *Atopy defined as serum specific IgE positivity
(> = .35 kU/l) to inhalant allergens; §above primary school, §§above high school.
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observed in both males and females but the strength of
these associations differed significantly between the twogenders (Table 2): For all four adiposity measures, the
estimated effect of adiposity changes on changes in
FEV1 and FVC were approximately three times higher
Figure 1 Changes of lung function according to weight changes.
Five-year changes of FEV1 (upper panel) and FVC (lower panel)
in quintiles of weight change in males (circles) and females
(diamonds). Quintile one-two include individuals with weight
loss, quintile four-five include individuals with weight gain. The
middle quintile is used as reference. Analysis adjusted for age,
tobacco use (pack years), and atopy.
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percentage changes were the double in males as com-
pared to females. For instance, for every one standard
deviation of weight change (5.4 kg) from baseline to follow-
up, FEV1 either increased or decreased with approxi-
mately 72 ml (66-78 ml) in males and 26 ml (21-31 ml) in
females, similarly FVC either increased or decreased with
111 ml (101-121 ml) in males and 35 ml (27-43 ml) in fe-
males. The metabolic markers, s-triglyceride, s-HDL, or
HOMA-IR did not attenuate the effects of adiposity mea-
sures on changes in FEV1 and FVC (data not shown).
Estimated mean declines for one year of increasing age
were approximately 32.8 (31.3-34.4) ml FEV1 and 21.4
(19.0-23.9) ml FVC. In never-smokers, the correspon-
ding estimates were 31.0 (28.7-33.3) ml FEV1and 21.0
(17.4-24.6) ml FVC. All age-estimates were essentially
similar in males and females but were significantly
smaller in younger than in older individuals.
The five-year adiposity changes had a differential impact
on lung function changes according to baseline adiposity
levels, as assessed as baseline BMI (Figure 2). Five-year
adiposity changes were associated with dose-dependentgreater declines of FEV1 and FVC in participants who
were overweight and obese at baseline as compared to
participants who were lean at baseline (Figure 2). Again,
this effect was significantly different in males and fe-
males but the interaction of baseline-BMI*five-year
changes of adiposity was only significant with respect to
FVC (p = 0.02). Essentially similar results can be ob-
tained by running our simulation example (Additional
file 1). There were not any associations between changes
of adiposity with changes of the FEV1/FVC-ratio between
baseline and follow-up. For one standard deviation change
of any adiposity measure, the FEV1/FVC-ratio changed
between −0.0023 (fat percentage) to 0.00097 (BMI) in
males (p-values 0.14-0.83) and this was not different in
females (p for interactions 0.66-0.99).
To further investigate the temporal relationship of asso-
ciations between changes in adiposity and lung function,
we performed ‘reverse’ analyses where baseline FEV1 and
FVC were used as explanatory variables for subsequent
adiposity changes. However, there were no such statisti-
cally significant associations. Thus, these results support
that changes in adiposity have an influence on lung func-
tion, but lung function does not have a similar influence
on changes in adiposity.
The inverse association of adiposity with lung func-
tion was confirmed in both persons with and without
asthma at baseline (Table 3). The gender differences in
lung function declines from baseline to follow-up were
also independent of asthma status at baseline (Table 3).
With respect to atopy and FENO -levels, there were es-
sentially no differences in the associations of adiposity
changes to changes of FEV1 and FVC between atopic
and non-atopic individuals or between persons with or
without elevated FENO-levels (Table 4). Analyses in
never- and non-smokers gave similar results (data not
shown).
Finally, we investigated whether baseline levels of adi-
posity measures or changes of adiposity levels from base-
line to follow-up were associated with incident asthma
and wheezing. The incidence of asthma and wheezing be-
tween baseline and follow-up was 7.0% (158/2265) and
5.9% (133/2263), respectively. There were no statistically
significant associations of any adiposity measure (baseline
or changes) with incident asthma but for changes of
weight and BMI there was a positive association with
wheezing (Table 5). Notably, the novel cases of asthma in
our cohort could be categorised as ‘late-onset’ asthma
because all participants were > =19 years at baseline.
Restricting our analysis further to novel cases of asthma and
wheezing in participants e.g. above > = 25 years or > = 40 years
yielded similar results. There were no differences between
atopic and non-atopic individuals or individuals with or
without elevated FENO-levels with respect to incident
asthma or wheezing (data not shown).
Table 2 Five-year changes of FEV (ml) and FVC (ml) in males and females per one standard deviation (1 sd) increase of
adiposity measure
Males Females
Est (ml) Se (ml) P Est (ml) Se (ml) p p-i
FEV1
Weight (1 sd) −72.6 5.8 <.001 −27.3 4.9 <.0001 <.001
BMI (1 sd) −78.5 6.5 <.001 −25.5 4.6 <.0001 <.001
WC (1 sd) −66.4 6.1 <.001 −23.4 4.8 <.0001 <.001
FatP (1 sd) −52.0 6.2 <.001 −19.2 4.9 <.0001 <.001
FVC
Weight (1 sd) −103.2 9.0 <.001 −36.2 7.6 <.0001 <.001
BMI (1 sd) −113.6 10.0 <.001 −32.6 7.1 <.0001 <.001
WC (1 sd) −90.7 9.4 <.001 −28.1 7.4 <.0001 <.001
FatP (1 sd) −54.3 9.7 <.001 −18.0 7.6 0.01 0.002
Linear regression models fitted with interaction between the specific adiposity measure and gender. Adjusted for age, atopy, tobacco use (pack years).
Est, beta-estimate; Se, standard error for Est; p, p-value; p-i, p-value for difference (interaction) between males and females; BMI, body mass index; WC,
waist circumference; FatP, fat percentage.
Figure 2 Changes of lung function according to weight
changes and baseline adiposity. Five-year changes of FEV1 (upper
panel) and FVC (lower panel) per one standard deviation increase of
weight between baseline and follow-up according to baseline levels
of BMI (X-axis) in males (circles) and females (diamonds), adjusted for
age, atopy, tobacco use (pack years), and atopy.
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We quantified the longitudinal relationship of several
adiposity measures, including waist circumference and
fat percentage, with lung function reflected by FEV1 and
FVC. Thus, we confirmed changes of FEV1 and FVC per
one kilo weight increase as summarised in Additional
file 2 and extended that knowledge by reporting longitu-
dinal estimates for abdominal adiposity (waist circumfer-
ence) and fat percentage. We found that an increase in
adiposity over five years was associated with declines in
FEV1 and FVC, whereas a decrease in adiposity was as-
sociated with increases of FEV1 and FVC. These associa-
tions were more pronounced in males than in females
but were independent of atopy and FENO -levels. Adi-
posity changes were not associated with changes in the
FEV1/FVC-ratio and were not associated with incident
asthma.
Adipose tissue and especially upper body fat have in
cross-sectional studies been shown to be associated with
decreased static lung volumes as assessed by functionalTable 3 Five-year changes of FEV1 (ml) and FVC (ml) in
males and females per one standard deviation increase
of BMI from baseline to follow-up, according to asthma
status at baseline
Males Females
Est Se p Est Se p
FEV1 Asthma −96.4 16.7 <.001 −10.7 10.8 0.32
Non-asthma −75.6 7.0 <.001 −29.1 5.2 <.001
FVC Asthma −109.7 24.4 <.001 −15.0 15.8 0.34
Non-asthma −115.0 11.0 <.001 −37.3 8.1 <.001
All models fitted with BMI-gender interaction (all interactions significant,
p ≤ .001) and adjusted for age, atopy, and smoking (pack years). BMI, body
mass index; Est, beta-estimate; Se, standard error; ml, milliliter; p, p-value
for Est.
Table 4 Five-year changes of FEV (ml) and FVC (ml) in non-atopic and atopic individuals (upper panel), and in individuals
with or without elevated FeNO-levels (lower panel), per one standard deviation increase of adiposity measures
Est (ml) Se (ml) P Est (ml) Se (ml) P p-i
Non-atopic Atopic
FEV1
Weight (1 sd) −46.0 4.2 <.001 −46.2 8.5 <.001 ns
BMI (1 sd) −42.3 4.2 <.001 −47.0 8.6 <.001 ns
WC (1 sd) −38.9 4.3 <.001 −43.1 8.3 <.001 ns
FatP (1 sd) −30.6 4.3 <.001 −35.8 8.5 <.001 ns
FVC
Weight (1 sd) −65.5 6.5 <.001 −59.3 13.1 <.001 ns
BMI (1 sd) −61.6 6.6 <.001 −54.8 13.2 <.001 ns
WC (1 sd) −53.2 6.6 <.001 −48.6 12.8 <.001 ns
Fat (1 sd) −32.3 6.7 <.001 −32.1 13.1 <.02 ns
Normal FeNO (<=20 ppb) Elevated FeNO (>20 ppb)
FEV1
Weight (1 sd) −45.6 4.7 <.001 −48.7 7.6 <.001 ns
BMI (1 sd) −43.4 4.7 <.001 −43.9 7.7 <.001 ns
WC (1 sd) −43.3 4.8 <.001 −31.7 7.2 <.001 ns
FatP (1 sd) −31.8 4.8 <.001 −24.3 7.4 <.001 ns
FVC
Weight (1 sd) −57.1 7.2 <.001 −85.2 12.6 <.001 0.04
BMI (1 sd) −54.5 7.2 <.001 −78.5 12.8 <.001 ns
WC (1 sd) −48.1 7.5 <.001 −59.4 11.9 <.001 ns
FatP (1 sd) −32.2 7.5 <.001 −28.1 12.4 <.02 ns
Linear regression models fitted with interaction between adiposity measure and either atopy or elevated FeNO and adjusted for age, atopy, and smoking (pack
years); p-i, p-values for interaction test. Est, beta-estimate; Se, standard error of Est; p, p-value; Atopy defined as serum specific IgE positivity (> = .35 kU/l) to in
halant allergens; FeNO, fractional expiratory nitric oxide;1 sd, one standard deviation; ns, non-significant; BMI, body mass index; WC, waist circumference; FatP,
fat percentage.
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As expiratory flow velocity is dependent on the degree of
previous lung inflation due to the elastic properties of the
lung [30], lower static lung volumes would subsequently
impact on expiratory flows. Our results support such
mechanical changes in a longitudinal setting. Firstly, the
longitudinal adiposity changes were inversely associated
with expiratory flow as reflected by FEV1. Secondly, pre-
existing adiposity (at baseline) enhanced the negative im-
pact of adiposity gain (Figure 2). Thus, the cumulative
mass of adipose tissue was associated with reduced lung
function as assessed by FEV1 and FVC. Adding that the
FEV1/FVC-ratio remained unchanged, there was not a
measurable increasing obstructive pattern with increasing
adiposity. In comparison, inflammatory mechanisms would
be expected to induce asthma-like, obstructive alterations
in lung function [31].
The gender differences in the adiposity-lung function
associations in this study were substantial, and may
emphasise the mechanical aspects as males have more
abdominal fat for the same degree of adiposity thanfemales [32]. Similar conclusions have been put for-
ward by authors in other studies [4,33,34] but supple-
mentary explanations may exist. At least in asthma
patients, recent cluster analyses have shown that a sub-
group of non-adipose males have a high yearly loss of
FEV1 that is not explained by presence or absence of
atopy, the duration of disease etc. [35,36]. This could
indicate that another pathological mechanism towards
declines of lung volumes occurs in those males, and
this could also apply to males without asthma. Differ-
ences in sex hormonal levels, which are emphasised by
decreasing gender differences in lung volume decline
in elderly [3] is a possible explanation for an apparently
different airway pathology in males and females. Other
possibilities are different thresholds for the detrimental
effects of pulmonary irritants, or differences in airway
calibre between males and females [37], although none
have been fully documented so far.
Atopy or FENO-levels did not modify the effects of
adiposity on lung function. Thus, an underlying atopic
as compared to non-atopic condition or an underlying
Table 5 The association of changes of adiposity measures (quartiles) between baseline and five-year follow-up with
risk of novel (incident) asthma and wheezing
Incident asthma Incident wheezing
N n n/N OR CI1 CI2 n n/N OR CI1 CI2
Weight Kg
q1 <−1.93 570 32 5.7 ref - - 26 4.7 ref - -
q2 1.93 - <0.7 573 47 8.3 1.47 0.91 2.42 27 4.7 0.89 0.48 1.63
q3 0.7 - <3.2 570 32 5.7 0.95 0.56 1.62 34 6.0 1.25 0.72 2.20
q4 >3.2 576 46 8.1 1.17 0.71 1.95 46 8.1 1.57 0.93 2.70
BMI Kg/m2
q1 <−0.57 572 36 6.4 ref - - 25 4.5 ref - -
q2 −0.57 - <0.31 572 43 7.6 1.17 0.72 1.90 27 4.8 1.02 0.56 1.86
q3 0.31 - <1.216 572 36 6.4 1.00 0.61 1.65 35 6.2 1.35 0.77 2.41
q4 >1.22 573 42 7.4 0.88 0.53 1.43 46 7.1 1.69 0.99 2.94
WC Cm
q1 <−1.5 564 30 5.4 Ref - - 27 4.9 ref - -
q2 −1.5 - <2 576 39 6.9 1.15 0.68 1.96 25 4.4 0.85 0.46 1.57
q3 2 - <5 525 45 8.7 1.62 0.98 2.71 43 8.3 1.67 0.98 2.91
q4 >5 626 43 6.9 1.14 0.69 1.91 38 6.2 1.27 0.74 2.22
FatP Percentage points
q1 <−1.40 569 32 5.7 ref - - 31 5.0 ref - -
q2 −1.40 - <0.50 570 47 8.3 1.45 0.89 2.38 34 6.0 1.13 0.66 1.96
q3 0.50 - <2.402 569 42 7.5 1.24 0.75 2.06 25 4.5 0.77 0.42 1.38
q4 >2.40 570 33 5.8 0.78 0.45 1.35 40 7.1 1.20 0.71 2.05
Number of participants in each group (N), number of novel cases (n) and age, gender, and tobacco (pack years) adjusted odds ratios (OR) with 95% confidence
intervals (CI1-CI2)); q1-q4, quartiles 1-4; BMI, body mass index; WC, waist circumference; FatP, Fat percentage.
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flammation did not appear to enhance the inverse asso-
ciation of adiposity with lung function in our general
population. It is possible that a characterisation of par-
ticipants by e.g. eosinophils in sputum or blood would
have yielded other results, as elevated FENO-levels only
are indicative of eosinophil airway inflammation [38].
For instance, cluster analyses have indicated that some
groups of asthma patients are characterised by eosino-
phil airway inflammation and low lung function [39].
Further, faster declines of lung volumes in non-atopic as
compared to atopic asthma patients have also been re-
ported [36,40,41]. However, our study was conducted in
a general population and not in specific groups of pa-
tients. Thus, absence of effect modification by atopy or
FENO-levels in our study appears to emphasise restrict-
ive changes of lung function with increasing adiposity.
However, our study was not powered to investigate ef-
fect modifications. Therefore, more studies are needed
to confirm or refute the presence of effect modification
by atopy or elevated FENO-levels.
We did not find an association between increasing adi-
posity and asthma incidence but for increasing weight
and BMI there was a positive association with incidentwheezing. This is in contrast with findings of most lon-
gitudinal studies, which have reported a positive associ-
ation between increasing BMI and incidence of asthma
[1]. However, the power to detect such differences in the
present study was relatively low as indicated by relatively
wide 95% confidence intervals. Possibly, testing the asso-
ciation of adiposity with bronchial hyperreactivity (BHR)
would have yielded other results; in a previous study we
found a positive association of adiposity with BHR [42],
but such information was not available in the current
study.
The strengths of the study include the prospective de-
sign, validated and similar methods for measurements of
FEV1 and FVC at baseline and follow-up, assessment of
atopy by serum specific IgE and airway eosinophil in-
flammation by FENO. The limitations include the lack of
tests for variability of lung function to define asthma,
lack of measures of lung volumes, and that the analyses
are based on the assumption that increases or decreases
of weight and BMI were due to adipose tissue and not
muscle mass. Selection bias may have decreased the gen-
eralisability of the study and loss to follow-up influenced
the reported associations. However, we found similar
baseline associations of adipose tissue measures with all
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follow-up indicating that our results may apply to a
general population.
Conclusion
In conclusion, changes of adiposity had a high, gender
specific impact on FEV1 and FVC but not on the FEV1/
FVC-ratio. Increasing adiposity was associated with lung
function decline, whereas loss of adiposity was associ-
ated with increasing lung function. These associations
were independent of atopy, FENO -levels, and metabolic
markers, but were modified by the level of adipose tissue
prior to the adiposity changes indicating the importance
of aggregate adipose tissue mass. The adiposity changes
leading to declines of FEV1 and FVC were not concomi-
tantly associated with incidence of asthma or wheezing,
however, a low number of novel cases of asthma and
wheezing may have limited the power to detect associa-
tions with these outcomes.
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